Literature DB >> 2454332

(+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates.

G A Ricaurte1, L S Forno, M A Wilson, L E DeLanney, I Irwin, M E Molliver, J W Langston.   

Abstract

(+/-)3,4-Methylenedioxymethamphetamine (MDMA) is a popular recreational drug that has been proposed to be useful as an adjunct to psychotherapy. This study assessed the neurotoxic potential of MDMA in nonhuman primates. Monkeys were repeatedly administered doses (2.50, 3.75, and 5.00 mg/kg) of MDMA subcutaneously and analyzed for regional brain content of serotonin and 5-hydroxyindoleacetic acid two weeks later. In all regions of the monkey brain examined, MDMA produced a selective dose-related depletion of serotonin and 5-hydroxyindoleacetic acid. These neurochemical deficits were associated with evidence of structural damage to serotonergic nerve fibers. In addition, MDMA produced pathological changes in nerve cell bodies in the dorsal, but not median, raphe nucleus. These results indicate that MDMA is a selective serotonergic neurotoxin in nonhuman primates and that humans using this drug may be at risk for incurring central serotonergic neuronal damage.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454332

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  60 in total

1.  Does recreational ecstasy use cause long-term cognitive problems?

Authors:  P A Kelly
Journal:  West J Med       Date:  2000-08

2.  Contrasting effects of d-methamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats.

Authors:  Pai-Kai Huang; Shawn M Aarde; Deepshikha Angrish; Karen L Houseknecht; Tobin J Dickerson; Michael A Taffe
Journal:  Drug Alcohol Depend       Date:  2012-06-03       Impact factor: 4.492

3.  Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users.

Authors:  Christina R Di Iorio; Tristan J Watkins; Mary S Dietrich; Aize Cao; Jennifer U Blackford; Baxter Rogers; Mohammed S Ansari; Ronald M Baldwin; Rui Li; Robert M Kessler; Ronald M Salomon; Margaret Benningfield; Ronald L Cowan
Journal:  Arch Gen Psychiatry       Date:  2011-12-05

4.  Neurotoxicity of methamphetamine and methylenedioxymethamphetamine.

Authors:  L S Seiden; R Lew; J E Malberg
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

5.  Alterations in hippocampal function following repeated exposure to the amphetamine derivative methylenedioxymethamphetamine ("Ecstasy").

Authors:  J Sharkey; D E McBean; P A Kelly
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

6.  Chronic cognitive impairment in users of 'ecstasy' and cannabis.

Authors:  Anthony Klugman; John Gruzelier
Journal:  World Psychiatry       Date:  2003-10       Impact factor: 49.548

Review 7.  Causes and consequences of methamphetamine and MDMA toxicity.

Authors:  Maria S Quinton; Bryan K Yamamoto
Journal:  AAPS J       Date:  2006-05-12       Impact factor: 4.009

8.  Psychomotor stimulant effects of d-amphetamine, MDMA and PCP: aggressive and schedule-controlled behavior in mice.

Authors:  K A Miczek; M Haney
Journal:  Psychopharmacology (Berl)       Date:  1994-07       Impact factor: 4.530

9.  Effects of a single dose of 3,4-methylenedioxymethamphetamine on circadian patterns, motor activity and sleep in drug-naive rats and rats previously exposed to MDMA.

Authors:  Brigitta Balogh; Eszter Molnar; Rita Jakus; Linda Quate; Henry J Olverman; Paul A T Kelly; Sandor Kantor; Gyorgy Bagdy
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

Review 10.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.